Patient-reported secondary outcomes
| Median (25th–75th percentile) | P value | |||
| Control-group | iAR-group | iLE-group | ||
| DCS (6) | 25 (16–38) | 22 (9–29) | 25 (7–31) | p=0.10* |
| Brief-IPQ (1) | 36 (26–42) | 34 (28–44) | 37 (30–42) | p=0.68 |
| Brief-IPQ (6) | 34 (26–43) | 35 (30–41) | 37 (29–44) | p=0.19 |
| PAM (1) | 60 (51–70) | 58 (53–68) | 63 (56–75) | p=0.20 |
| PAM (6) | 64 (54–77) | 63 (56–77) | 63 (56–78) | p=0.48 |
| Perceived Statin Efficacy (1) | 8 (7–9) | 8 (7–9) | 8 (7–9) | p=0.92* |
| Perceived Statin Efficacy (6) | 8 (7–9) | 8 (7–9) | 8 (7–9) | p=0.98* |
| Understanding of therapy-effects (1) | 88 (75–88) | 88 (75–100) | 88 (75–100) | p=0.07* |
| Understanding of therapy-effects (6) | 88 (75–100) | 88 (75–100) | 88 (63–100) | p=0.60* |
| BMQ Adherence Risk Scale (1) | 1 (0–1) | 1 (0–1) | 1 (0–1) | p=0.60* |
| BMQ Adherence Risk Scale (6) | 1 (0–1) | 1 (0–1) | 1 (0–1) | p=0.41* |
| SDMQ-9 (1); reported visiting GP (n) | 44 (9–69); (46) | 42 (18–62); (58) | 58 (22–76); (55) | p=0.40* |
| SDMQ-9 (6); reported visiting GP (n) | 44 (24–73); (60) | 48 (32–63); (49) | 62 (22–84); (47) | p=0.28* |
| RAND-36 Quality of life (6) | ||||
| Physical functioning | 80 (70–85) | 75 (60–85) | 80 (65–85) | p=0.11* |
| Role limitations due to physical health | 80 (70–85) | 75 (60–85) | 80 (65–85) | p=0.57* |
| Role limitations due to emotional problems | 100 (100–100) | 100 (100–100) | 100 (100–100) | p=0.80* |
| Energy/fatigue | 75 (65–80) | 70 (60–80) | 73 (55–80) | p=0.20* |
| Emotional well-being | 84 (73–92) | 84 (72–92) | 80 (72–88) | p=0.11* |
| Social functioning | 88 (75–88) | 88 (63–88) | 88 (75–88) | p=0.49* |
| Pain | 90 (78–100) | 90 (68–100) | 100 (78–100) | p=0.93* |
| General health | 70 (55–75) | 60 (49–75) | 65 (50–74) | p=0.10* |
Data are for 1 or 6 months. Bonferroni p-value for significance was 0.002.
*A non-parametric test was applied.
BMQ, Brief Medication Questionnaire; Brief-IPQ, Brief Illness Perception Questionnaire; DCS, Decisional Conflict Scale; PAM, Patient Activation Measure; SDMQ-9, Shared Decision Making Questionnaire.